Patient-Reported Outcomes with Roflumilast Foam 0.3% in Patients with Psoriasis of the Scalp and Body in the Phase 3 ARRECTOR Trial
Main Article Content
Keywords
scalp psoriasis, roflumilast, topical
Abstract
Introduction: Patients with psoriasis of the scalp or body consider itch the most burdensome symptom. Roflumilast is a highly potent phosphodiesterase 4 inhibitor under investigation as a novel, once-daily foam for treatment of psoriasis of the scalp and body. The impact of roflumilast foam 0.3% on patient-reported outcomes (PROs) in patients with psoriasis of the scalp and body from the phase 3 trial (ARRECTOR; NCT05028582) are reported here.
Methods: Patients aged ≥12 years with psoriasis of the scalp and body affecting ≤25% of overall body surface area, minimum Scalp-Investigator Global Assessment (S‑IGA) of Moderate, and minimum Body-IGA (B-IGA) of Mild were randomized 2:1 to once-daily roflumilast foam 0.3% or vehicle for 8 weeks. PROs included the Psoriasis Symptom Diary (PSD; ≥18 years only), Scalpdex, Dermatology Life Quality Index (DLQI; ≥17 years only), Scalp Itch- and Worst Itch-Numeric Rating Scale (SI-NRS and WI‑NRS, respectively; each rated from 0 [no itch] to 10 [worst itch imaginable]).
Results: Overall, 281 patients were treated with roflumilast foam 0.3% and 151 were treated with vehicle. In patients with SI-NRS and/or WI-NRS ≥2 at baseline, significantly greater proportions of the roflumilast group than the vehicle group achieved scores of 0 or 1 at Week 8 for SI-NRS (52.3% vs 24.1%; P<0.0001) and/or WI‑NRS (55.4% vs 19.8%; P<0.0001). Similar improvements were observed in other PROs at Week 8, with a significantly greater proportion of the roflumilast group achieving PSD total scores of 0 (19.6% vs 7.1%; P=0.0012). The roflumilast group also had significantly greater reductions in least-squares mean change from baseline in PSD items related to itching/pain/scaling (–10.9 vs –5.8; P<0.0001), Scalpdex score (–23.4 vs –12.8; P<0.0001), and DLQI (–4.4 vs –2.4; P<0.0001).
Conclusion: Roflumilast foam 0.3% improved quality of life, including patient reported itching, pain, and scaling, related to psoriasis of the scalp and body.
Sponsorship: Arcutis Biotherapeutics, Inc.
References
2. Callis Duffin K, et al. Dermatology. 2021;237:46–55.
3. Egeberg A, et al. BMC Dermatol. 2020;20:3.
4. van de Kerkhof PC, et al. Dermatology. 1998;197:31–36.
5. Dong C, et al. J Pharmacol Exp Ther. 2016;358:413–422.
6. Wang J, et al. J Investig Dermatol. Published online ahead of print November 26, 2024. doi:10.1016/j.jid.2024.10.597.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.